Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.76 |
| ▸ | TSHR | P16473 | 2/20 | 0.76 |
| ▸ | THPO | P40225 | 2/20 | 0.76 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.76 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.76 |
| ▸ | GLA | P06280 | 1/20 | 0.76 |
| ▸ | EIF4E | P06730 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
| ▸ | TOP1 | P11387 | 1/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Taribavirin SCHEMBL3868643 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL2619250 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL18735565 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL3307695 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL3307685 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL6981526 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL12758161 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL16330745 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL2631656 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL40670 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3694512-A1 | METHODS FOR TREATING HCV | Abbvie Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| WO-2019074507-A1 | METHODS FOR TREATING HCV | ABBVIE INC. (US) | 2019-04-18 | — | — | WO | disclosed |
| WO-2017133517-A1 | PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF | 四川海思科制药有限公司 | 2017-08-10 | — | — | WO | disclosed |
| EP-3125890-A1 | METHODS FOR TREATING HCV | AbbVie Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| EP-3082808-A1 | METHODS FOR TREATING LIVER TRANSPLANT RECIPIENTS | AbbVie Inc. (US) | 2016-10-26 | — | — | EP | disclosed |
| WO-2016134058-A1 | COMBINATIONS USEFUL TO TREAT HEPATITIS C VIRUS | ABBVIE INC. (US) | 2016-08-25 | — | — | WO | disclosed |
| EP-2968302-A1 | COMBINATION OF DIRECT ACTING ANTIVIRAL AGENTS AND RIBAVIRIN FOR TREATING HCV PATIENTS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015153792-A1 | METHODS FOR TREATING HCV | ABBVIE INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015095572-A1 | METHODS FOR TREATING LIVER TRANSPLANT RECIPIENTS | ABBVIE INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2014152635-A9 | COMBINATION OF DIRECT ACTING ANTIVIRAL AGENTS AND RIBAVIRIN FOR TREATING HCV PATIENTS | ABBVIE INC. (US) | 2014-12-11 | — | — | WO | disclosed |
| WO-2014152635-A1 | COMBINATION OF DIRECT ACTING ANTIVIRAL AGENTS AND RIBAVIRIN FOR TREATING HCV PATIENTS | ABBVIE INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2013059630-A1 | METHODS FOR TREATING HCV COMPRISING AT LEAST TWO DIRECT ACTING ANTIVIRAL AGENT, RIBAVIRIN BUT NOT INTERFERON. | ABBVIE INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| EP-1257281-B8 | NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE | VALEANT PHARMACEUTICALS NORTH (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1257281-A4 | NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE | ICN PHARMACEUTICALS (US) | 2003-03-19 | — | — | EP | disclosed |
| EP-1257281-A1 | NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE | ICN Pharmaceuticals, Inc. (US) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001060379-A1 | NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE | RIBAPHARM CORP. (US) | 2001-08-23 | — | — | WO | disclosed |